LONDON, UK, Thursday, May 31, 2007 - SkyePharma PLC (LSE: SKP) today announces that the U.S. Food and Drug Administration (FDA) has approved Critical Therapeutics, Inc.'s (Nasdaq: CRTX) New Drug Application (NDA) for twice-daily ZYFLO CR™ (zileuton) extended-release tablets. ZYFLO CR uses SkyePharma PLC’s proprietary Geomatrix® drug delivery technology, which controls the amount and rate of drug released into the body.
